Nuformix Regulatory News (NFX)

22 June 2020

Nuformix plc

("Nuformix" or the "Company")

Board Change

Nuformix announces the resignation of Dr. Dan Gooding, Chief Executive Officer. Whilst he will step down from the Company's board of directors with immediate effect, he has agreed to stay until the end of June 2020 to conduct an orderly handover. 

Dr. Christopher Blackwell, Chairman, will lead the Company as Executive Chairman until a successor is found.  

Dr. Blackwell, said: "On behalf of the board, I would like to thank Dan for his contribution to Nuformix. We wish Dan all the best in the future."

Dr. Dan Gooding said "We set up what is now Nuformix plc twelve years ago. To have been involved at its heart as a co-founder from the first day through to listing on the main market and beyond has been an enormous privilege and I am immensely proud of all that we have achieved. Now is the right time for me to step aside and move on to other projects. The Company has multiple exciting opportunities ahead and I wish the team and the business every success."

- Ends -

Enquiries:

About Nuformix plc 

Nuformix is a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs. Nuformix risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel forms of approved small molecules.

Nuformix is targeting high-value unmet needs via drug repurposing with a lead programme in fibrosis (NXP002).

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX. For more information please visit www.nuformix.com.